121 related articles for article (PubMed ID: 17953445)
1. Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.
Kaminskas LM; Boyd BJ; Karellas P; Henderson SA; Giannis MP; Krippner GY; Porter CJ
Mol Pharm; 2007; 4(6):949-61. PubMed ID: 17953445
[TBL] [Abstract][Full Text] [Related]
2. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.
Boyd BJ; Kaminskas LM; Karellas P; Krippner G; Lessene R; Porter CJ
Mol Pharm; 2006; 3(5):614-27. PubMed ID: 17009860
[TBL] [Abstract][Full Text] [Related]
3. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
5. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.
Kaminskas LM; Kota J; McLeod VM; Kelly BD; Karellas P; Porter CJ
J Control Release; 2009 Dec; 140(2):108-16. PubMed ID: 19686787
[TBL] [Abstract][Full Text] [Related]
6. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Owen DJ; Boyd BJ; Porter CJ
J Control Release; 2011 Jun; 152(2):241-8. PubMed ID: 21315119
[TBL] [Abstract][Full Text] [Related]
7. Inducing a change in the pharmacokinetics and biodistribution of poly-L-lysine in rats by complexation with heparin.
Johnston TP; Kuchimanchi KR; Alur H; Chittchang M; Mitra AK
J Pharm Pharmacol; 2003 Aug; 55(8):1083-90. PubMed ID: 12956897
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration.
Okuda T; Kawakami S; Maeie T; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Aug; 114(1):69-77. PubMed ID: 16814896
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization, and gene delivery of poly-L-lysine octa(3-aminopropyl)silsesquioxane dendrimers: nanoglobular drug carriers with precisely defined molecular architectures.
Kaneshiro TL; Wang X; Lu ZR
Mol Pharm; 2007; 4(5):759-68. PubMed ID: 17705440
[TBL] [Abstract][Full Text] [Related]
10. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers.
Agashe HB; Babbar AK; Jain S; Sharma RK; Mishra AK; Asthana A; Garg M; Dutta T; Jain NK
Nanomedicine; 2007 Jun; 3(2):120-7. PubMed ID: 17572354
[TBL] [Abstract][Full Text] [Related]
11. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
12. Partly-PEGylated Poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers.
Kaminskas LM; Wu Z; Barlow N; Krippner GY; Boyd BJ; Porter CJ
J Pharm Sci; 2009 Oct; 98(10):3871-5. PubMed ID: 19283758
[TBL] [Abstract][Full Text] [Related]
13. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice.
Okuda T; Kawakami S; Akimoto N; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Dec; 116(3):330-6. PubMed ID: 17118476
[TBL] [Abstract][Full Text] [Related]
14. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate.
Agrawal P; Gupta U; Jain NK
Biomaterials; 2007 Aug; 28(22):3349-59. PubMed ID: 17459469
[TBL] [Abstract][Full Text] [Related]
15. [The receptor of serpentine type and the heterotrimeric G protein as targets of action of the polylysine dendrimers].
Shpakov AO; Gur'ianov IA; Baianova NV; Vlasov GP
Tsitologiia; 2008; 50(12):1036-43. PubMed ID: 19198542
[TBL] [Abstract][Full Text] [Related]
16. In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia.
Watanabe K; Harada-Shiba M; Suzuki A; Gokuden R; Kurihara R; Sugao Y; Mori T; Katayama Y; Niidome T
Mol Biosyst; 2009 Nov; 5(11):1306-10. PubMed ID: 19823746
[TBL] [Abstract][Full Text] [Related]
17. Chain length effects of oligo(L-lysine)-shelled dendrimers on interaction with DNA.
Higashi N; Uchino A; Mizuguchi Y; Niwa M
Int J Biol Macromol; 2006 Mar; 38(2):120-5. PubMed ID: 16546250
[TBL] [Abstract][Full Text] [Related]
18. The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers.
Lim J; Guo Y; Rostollan CL; Stanfield J; Hsieh JT; Sun X; Simanek EE
Mol Pharm; 2008; 5(4):540-7. PubMed ID: 18672950
[TBL] [Abstract][Full Text] [Related]
19. An expeditious multigram-scale synthesis of lysine dendrigraft (DGL) polymers by aqueous N-carboxyanhydride polycondensation.
Collet H; Souaid E; Cottet H; Deratani A; Boiteau L; Dessalces G; Rossi JC; Commeyras A; Pascal R
Chemistry; 2010 Feb; 16(7):2309-16. PubMed ID: 20033966
[TBL] [Abstract][Full Text] [Related]
20. How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo.
Shcharbin D; Janaszewska A; Klajnert-Maculewicz B; Ziemba B; Dzmitruk V; Halets I; Loznikova S; Shcharbina N; Milowska K; Ionov M; Shakhbazau A; Bryszewska M
J Control Release; 2014 May; 181():40-52. PubMed ID: 24607663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
